Here are the 8-K filings from Atrium Therapeutics, Inc. (RNA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow RNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RNA filings page.
Atrium Therapeutics, Inc. (RNA) said it will present nonclinical results for ATR 1072, its investigational PRKAG2 syndrome therapy, on November 6, 2026, at HCMS during the American Heart Association Scientific Sessions. In a company-developed mouse model, mice received one dose of mATR 1072, a mouse surrogate, after disease features had been established for three weeks. Four weeks after treatment, cardiac glycogen accumulation was reversed, while cardiac hypertrophy and ECG parameters improved.
Corventis is a Phase 1/2 open-label trial that will enroll approximately 37 participants. Atrium expects initial proof-of-concept data in the second half of 2027. The trial’s primary endpoint is treatment-emergent adverse events; secondary measures include PRKAG2 mRNA reduction and siRNA tissue concentrations.
The corporate presentation lists $264 million in cash, cash equivalents and investments as of June 30, 2026, with runway through the end of 2028. That runway excludes the $15 million milestone earned from Bristol Myers Squibb, announced August 13, 2026, and proceeds from the $50 million private placement announced October 8, 2026. It also lists $1.5 billion in potential R&D milestone payments from existing BMS and LLY collaborations, subject to the agreements’ terms and conditions.
Atrium Therapeutics, Inc. (RNA) announced that the first patient has been dosed in the Phase 1/2 Corventis trial evaluating ATR 1072, an investigational therapy for the potential treatment of PRKAG2 syndrome. The open-label, multicenter study is designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy, and is expected to enroll approximately 37 participants across multiple-ascending-dose and single-arm expansion parts.
The primary endpoint is the incidence of treatment-emergent adverse events; secondary and exploratory measures include PRKAG2 mRNA reduction, siRNA tissue concentrations and plasma pharmacokinetics. Atrium expects initial proof-of-concept data in the second half of 2027.
Atrium Therapeutics, Inc. amended its earlier 8-K to correct the post-offering count to 21,571,507 common shares outstanding. On October 7, 2026, the company entered into a securities purchase agreement with selected accredited investors to sell 5,170,384 common shares and pre-funded warrants to purchase up to 1,134,930 shares.
The post-offering count includes shares issued in connection with settlement of make-whole equity awards made in connection with the company’s spin-off from Avidity Biosciences. Atrium described the offering’s closing as expected and cited closing conditions and timing as risks.
Atrium Therapeutics, Inc. (RNA) agreed to sell 5,170,384 common shares and pre-funded warrants to purchase up to 1,134,930 shares in a private placement expected to generate approximately $50 million in gross proceeds before placement agent fees and other offering expenses.
Shares were priced at $7.93 each and warrants at $7.929 each, with a $0.001 exercise price. Warrants are exercisable after issuance and expire when exercised in full. Exercise is limited by a 9.99% ownership cap, or 4.99% at the holder’s election; after at least 61 days’ prior notice, the holder may change the cap to another percentage up to 19.99%. Closing is expected on or about October 9, 2026, subject to customary conditions.
Atrium plans to use net proceeds and existing cash, cash equivalents and marketable securities for its lead candidates, other research programs, working capital and general corporate purposes, and estimates these resources will fund operations through 2028. Following the Offering, it expects 22,276,027 common shares outstanding, including shares issued in connection with settlement of make-whole equity awards. Atrium agreed to file a resale registration statement covering the Shares and Warrant Shares within 50 days of the Closing Date.
Atrium Therapeutics reported second-quarter 2026 results and highlighted key R&D milestones. The company received FDA IND clearance for ATR 1072 for PRKAG2 syndrome and initiated Corventis, its first Phase 1/2 clinical trial and first clinical study targeting this disease. Atrium also achieved a second milestone payment under its global cardiovascular collaboration with Bristol Myers Squibb.
For the quarter ended June 30, 2026, Atrium generated $3.0 million in collaboration revenue and recorded a net loss of about $20.2 million, or $1.18 per share. For the first six months of 2026, collaboration revenue was $22.6 million, while the net loss totaled approximately $36.8 million. Operating expenses reflect continued investment in R&D and company build-out.
As of June 30, 2026, Atrium reported $72.3 million in cash and cash equivalents and $191.6 million in short-term investments, supporting its precision cardiology pipeline, including ATR 1072, ATR 1086 for PLN cardiomyopathy, and additional rare cardiomyopathy programs.
Atrium Therapeutics announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for ATR 1072, enabling initiation of the Corventis Phase 1/2 trial in PRKAG2 syndrome.
Corventis is an open-label, multicenter study enrolling approximately 37 participants, with multiple ascending dose cohorts followed by an expansion cohort at a recommended Phase 2 dose. The company expects first enrollment by the end of 2026 and initial proof-of-concept data in the second half of 2027. ATR 1072 uses small interfering RNA to silence mutant PRKAG2 messenger RNA with the goal of normalizing AMPK activity and reducing glycogen accumulation in this rare cardiomyopathy, which is estimated to affect 1,000–2,000 people in the U.S.
Atrium Therapeutics, Inc. reported first quarter 2026 results following its launch as a public precision cardiology company. For the three months ended March 31, 2026, collaboration revenue was $19,635 thousand, up from $1,573 thousand a year earlier.
Total operating expenses rose to $36,915 thousand from $9,025 thousand, driven by higher research and development and general and administrative spending. Atrium recorded a net loss of $16,633 thousand, versus $7,449 thousand in the prior-year period, equal to a basic and diluted net loss per share of $0.97 compared with $0.44.
On the balance sheet as of March 31, 2026, cash and cash equivalents were $267,849 thousand, total assets were $292,360 thousand, and total liabilities were $58,256 thousand, resulting in stockholders’ equity of $234,104 thousand.